341 related articles for article (PubMed ID: 28120389)
1. Modulating the wnt signaling pathway with small molecules.
Tran FH; Zheng JJ
Protein Sci; 2017 Apr; 26(4):650-661. PubMed ID: 28120389
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Liu Z; Wang P; Wold EA; Song Q; Zhao C; Wang C; Zhou J
J Med Chem; 2021 Apr; 64(8):4257-4288. PubMed ID: 33822624
[TBL] [Abstract][Full Text] [Related]
3. Polycyclic aromatic hydrocarbons and dibutyl phthalate disrupt dorsal-ventral axis determination via the Wnt/β-catenin signaling pathway in zebrafish embryos.
Fairbairn EA; Bonthius J; Cherr GN
Aquat Toxicol; 2012 Nov; 124-125():188-96. PubMed ID: 22975441
[TBL] [Abstract][Full Text] [Related]
4. Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Roos J; Grösch S; Werz O; Schröder P; Ziegler S; Fulda S; Paulus P; Urbschat A; Kühn B; Maucher I; Fettel J; Vorup-Jensen T; Piesche M; Matrone C; Steinhilber D; Parnham MJ; Maier TJ
Pharmacol Ther; 2016 Jan; 157():43-64. PubMed ID: 26549540
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation.
Lu W; Tinsley HN; Keeton A; Qu Z; Piazza GA; Li Y
Eur J Pharmacol; 2009 Jan; 602(1):8-14. PubMed ID: 19026633
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction.
Wang S; Yin J; Chen D; Nie F; Song X; Fei C; Miao H; Jing C; Ma W; Wang L; Xie S; Li C; Zeng R; Pan W; Hao X; Li L
Nat Chem Biol; 2013 Sep; 9(9):579-85. PubMed ID: 23892894
[TBL] [Abstract][Full Text] [Related]
7. Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy.
Liu D; Chen L; Zhao H; Vaziri ND; Ma SC; Zhao YY
Biomed Pharmacother; 2019 Sep; 117():108990. PubMed ID: 31226638
[TBL] [Abstract][Full Text] [Related]
8. Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine.
Lum L; Chen C
Curr Med Chem; 2015; 22(35):4091-103. PubMed ID: 26310918
[TBL] [Abstract][Full Text] [Related]
9. The anti-cancer activity of an andrographolide analogue functions through a GSK-3β-independent Wnt/β-catenin signaling pathway in colorectal cancer cells.
Reabroi S; Saeeng R; Boonmuen N; Kasemsuk T; Saengsawang W; Suksen K; Zhu W; Piyachaturawat P; Chairoungdua A
Sci Rep; 2018 May; 8(1):7924. PubMed ID: 29784906
[TBL] [Abstract][Full Text] [Related]
10. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
Vallée A; Lecarpentier Y; Vallée JN
Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
[TBL] [Abstract][Full Text] [Related]
12. Distinctive microRNA signature associated of neoplasms with the Wnt/β-catenin signaling pathway.
Sun X; He Y; Huang C; Ma TT; Li J
Cell Signal; 2013 Dec; 25(12):2805-11. PubMed ID: 24041653
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.
Huang SM; Mishina YM; Liu S; Cheung A; Stegmeier F; Michaud GA; Charlat O; Wiellette E; Zhang Y; Wiessner S; Hild M; Shi X; Wilson CJ; Mickanin C; Myer V; Fazal A; Tomlinson R; Serluca F; Shao W; Cheng H; Shultz M; Rau C; Schirle M; Schlegl J; Ghidelli S; Fawell S; Lu C; Curtis D; Kirschner MW; Lengauer C; Finan PM; Tallarico JA; Bouwmeester T; Porter JA; Bauer A; Cong F
Nature; 2009 Oct; 461(7264):614-20. PubMed ID: 19759537
[TBL] [Abstract][Full Text] [Related]
14. The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome.
Zhang L; Adu IK; Zhang H; Wang J
Int Urol Nephrol; 2023 Oct; 55(10):2527-2538. PubMed ID: 36964322
[TBL] [Abstract][Full Text] [Related]
15. The potential of targeting Wnt/β-catenin in colon cancer.
Sebio A; Kahn M; Lenz HJ
Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
[TBL] [Abstract][Full Text] [Related]
16. Emergence of TNIK inhibitors in cancer therapeutics.
Yamada T; Masuda M
Cancer Sci; 2017 May; 108(5):818-823. PubMed ID: 28208209
[TBL] [Abstract][Full Text] [Related]
17. Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis.
Madan B; Patel MB; Zhang J; Bunte RM; Rudemiller NP; Griffiths R; Virshup DM; Crowley SD
Kidney Int; 2016 May; 89(5):1062-1074. PubMed ID: 27083283
[TBL] [Abstract][Full Text] [Related]
18. Wnt signaling pathway in non-small cell lung cancer.
Stewart DJ
J Natl Cancer Inst; 2014 Jan; 106(1):djt356. PubMed ID: 24309006
[TBL] [Abstract][Full Text] [Related]
19. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
